The national genomic test directory specifies which genomic tests are commissioned by the NHS in England and the patients who are eligible to access to each test. The directory is regularly updated and clinicians should check the current version of the directory before referring patients.
Access the current edition of the directory (opens in a new tab). Please review this information and the NHSE published documents to ensure you are aware of any updates that may affect your practice.
Updates to the directory are made once they are approved by the NHS and are summarised below. From the time of the update, it can take up to three months for significant changes and new tests to become fully available. This is due to the time it can take to develop, implement and verify new testing procedures.
June 2023
| Clinical Indication ID | Clinical Indication |
|---|---|
| Clinical Indication ID R444 | Clinical Indication NICE approved PARP inhibitor treatment |
An additional Clinical Indication has been added to the Rare and Inherited Disease Test Directory to support NICE-approved PARP inhibitor treatment in breast and prostate cancer. The Rare and Inherited Disease eligibility criteria document has also been updated.
The R444 Clinical Indication code should be used for germline testing in patients not eligible for testing via R208 (breast) or R430 (prostate) testing.